Patient and graft characteristics
| Variable . | Treg recipients . | Siro/MMF controls . |
|---|---|---|
| Number of patients | 11 | 22 |
| Median age, y (range) | 61 (45-68) | 60 (34-69) |
| Males | 6 (55%) | 20 (91%) |
| HCT Comorbidity Index | ||
| 0 | 3 (27%) | 8 (36%) |
| 1-2 | 4 (36%) | 9 (41%) |
| 3+ | 4 (36%) | 5 (23%) |
| Recipient CMV+ | 6 (55%) | 7 (32%) |
| Diagnosis | ||
| ALL/AML | 6 (54%) | 13 (59%) |
| CLL | 2 (18%) | 2 (9%) |
| NHL/HL | 2 (18%) | 5 (23%) |
| Other* | 1 (9%) | 2 (10%) |
| High-risk disease | 5 (45%) | 10 (45%) |
| HLA disparity† | ||
| 4/6 + 4/6 | 3 (27%) | 7 (32%) |
| 4/6 + 5/6 | 1 (9%) | 4 (18%) |
| 4/6 + 6/6 | 1 (9%) | 0 |
| 5/6 + 5/6 | 4 (36%) | 6 (27%) |
| 5/6 + 6/6 | 1 (9%) | 2 (9%) |
| 6/6 +6/6 | 1 (9%) | 3 (14%) |
| Median combined TNC × 107 cells/kg (range) (IQR) | 4.2 (3.0-9.2) (3.3-4.7) | 3.9 (2.8-7.7) (3.3-4.7) |
| Median combined CD34+ × 105 cells/kg (range) (IQR) | 5.2 (2.7-11.9) (4.3-8.1) | 4.9 (2.0-18.3) (3.3-8.3) |
| Median combined CD3+ × 107 cells/kg (range) (IQR) | 1.6 (1.0-4.0) (1.3-1.8) | 1.6 (1.0-7.6) (1.3-2.0) |
| Variable . | Treg recipients . | Siro/MMF controls . |
|---|---|---|
| Number of patients | 11 | 22 |
| Median age, y (range) | 61 (45-68) | 60 (34-69) |
| Males | 6 (55%) | 20 (91%) |
| HCT Comorbidity Index | ||
| 0 | 3 (27%) | 8 (36%) |
| 1-2 | 4 (36%) | 9 (41%) |
| 3+ | 4 (36%) | 5 (23%) |
| Recipient CMV+ | 6 (55%) | 7 (32%) |
| Diagnosis | ||
| ALL/AML | 6 (54%) | 13 (59%) |
| CLL | 2 (18%) | 2 (9%) |
| NHL/HL | 2 (18%) | 5 (23%) |
| Other* | 1 (9%) | 2 (10%) |
| High-risk disease | 5 (45%) | 10 (45%) |
| HLA disparity† | ||
| 4/6 + 4/6 | 3 (27%) | 7 (32%) |
| 4/6 + 5/6 | 1 (9%) | 4 (18%) |
| 4/6 + 6/6 | 1 (9%) | 0 |
| 5/6 + 5/6 | 4 (36%) | 6 (27%) |
| 5/6 + 6/6 | 1 (9%) | 2 (9%) |
| 6/6 +6/6 | 1 (9%) | 3 (14%) |
| Median combined TNC × 107 cells/kg (range) (IQR) | 4.2 (3.0-9.2) (3.3-4.7) | 3.9 (2.8-7.7) (3.3-4.7) |
| Median combined CD34+ × 105 cells/kg (range) (IQR) | 5.2 (2.7-11.9) (4.3-8.1) | 4.9 (2.0-18.3) (3.3-8.3) |
| Median combined CD3+ × 107 cells/kg (range) (IQR) | 1.6 (1.0-4.0) (1.3-1.8) | 1.6 (1.0-7.6) (1.3-2.0) |
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CD cluster of differentiation; CLL, chronic lymphocytic leukemia; CMV, cytomegalovirus; HCT, hematopoietic stem cell transplantation–specific comorbidity index; HL, non-Hodgkin lymphoma; HLA, human leukocyte antigen; IQR, interquartile range; NHL, non-Hodgkin lymphoma; Siro/MMF, sirolimus/mycohenolate mofetil; TNC, total nucleated cell dose.
Includes 1 patient with myeloma in each group and 1 patient with myeloproliferative disease.
HLA disparity considers the worst matched of the 2 donor units.